ADMA Biologics Earnings Call: ASCENIV Fuels Profits

ADMA Biologics Inc ((ADMA)) has held its Q1 earnings call. Read on for the main highlights of the call.

ADMA Biologics’ latest earnings call struck a cautiously upbeat tone, as management highlighted powerful momentum from flagship therapy ASCENIV against a backdrop of turbulence in the broader immunoglobulin market. The company stressed that robust margins, cash generation and pipeline progress leave it well positioned, even as standard IG pricing pressure and channel disruption cloud the near term.

ASCENIV Drives Double-Digit Growth

ASCENIV remained the clear growth engine, generating $97.5 million in Q1 2026 revenue, up about 28% year over year on record end‑market demand and new patient starts. Management pointed to growing prescriber adoption and strong patient adherence, noting that April’s run rate tracked in line with Q1 direct sales, suggesting momentum is carrying into the second quarter.

Margin Expansion Boosts Profitability

The earnings mix shift toward ASCENIV helped lift gross profit to $80.8 million, translating into a gross margin of 71% versus 53% a year ago. Management credited both the richer product mix and yield‑enhanced manufacturing processes, which allow more efficient use of high‑titer plasma and support structurally higher margins.

EBITDA and Net Income Move Higher

Improved margins translated into stronger profitability, with adjusted EBITDA rising 24% year over year to $59.7 million. Adjusted net income increased roughly 22% to $40.7 million, while GAAP net income reached $45.3 million, underscoring that ADMA is now converting top‑line strength into meaningful bottom‑line gains.

Cash Generation and Liquidity Strengthen

ADMA delivered approximately $58 million of operating cash flow in Q1 2026, surpassing the total it produced in all of 2025. The company ended the quarter with $138 million in cash and cash equivalents and pro forma net leverage below 0.5 times, while retaining about $100 million of additional borrowing capacity, giving it ample financial flexibility.

Capital Returns and Balance Sheet Actions

The company continued to actively manage its capital structure, executing accelerated stock repurchases that converted roughly 3.6% of shares into treasury stock. Management emphasized it still has room to pursue opportunistic buybacks while funding growth initiatives, suggesting confidence in both the balance sheet and future cash flows.

Operational and Supply Chain Enhancements

On the operations front, ADMA completed the monetization of three plasma centers while bringing on a new third‑party plasma supplier, diversifying its sourcing base. The company now relies on a balanced mix of internal and external plasma procurement and continues to use yield‑enhanced manufacturing for ASCENIV to maximize utilization of high‑titer plasma.

Pipeline Progress and Regulatory Catalysts

Pipeline development added another positive layer, with ASCENIV securing pediatric label expansion to broaden its addressable population. ADMA is preparing for a pre‑IND interaction on SG‑001 later in 2026, and preclinical data will be presented at an upcoming conference, with management sizing a potential peak market opportunity in the $300 million to $500 million range if the candidate ultimately succeeds.

BIVIGAM Hit by Market Disruption

Set against ASCENIV’s strength, BIVIGAM revenue slumped to $15.4 million in Q1, down 54% from a year earlier as distributor ordering patterns turned volatile. Management cited aggressive discounting and rebate strategies from newer competitors in the standard IG segment as a key driver of this shortfall.

Flat Overall Revenue Masks Mix Shift

Total company revenue was essentially flat at $114.5 million compared with $114.8 million a year ago, reflecting the cross‑currents within the portfolio. ASCENIV’s strong growth was offset by the steep BIVIGAM decline and roughly $3 million less in intermediate and other product sales, marking a meaningful shift toward higher‑value therapies even without headline growth.

Pricing Pressure Undercuts Standard IG

Management described the standard IG arena as intensely competitive, with some new entrants cutting prices 15% to 20% from their original launch levels through discounts and rebates. This pricing pressure has contributed to channel disruption, reduced reported revenue for products like BIVIGAM and heightened uncertainty around near‑term standard IG volumes.

Inventory Build and Channel Dislocation

Industry‑wide dynamics also weighed on results, as surplus raw plasma supply and elevated finished‑goods inventories in distribution triggered changed ordering patterns in Q1. ADMA characterized these factors as transitory but acknowledged the timing of normalization is uncertain, making quarterly revenue for standard IG products more variable.

Elevated DSOs and Working Capital Focus

The company’s days sales outstanding climbed to about 107 days in Q1 2026, slightly above its 90 to 105 day target range and posing a near‑term drag on working capital. Management expects DSOs to improve in the back half of the year as ordering stabilizes and the McKesson Specialty partnership ramps, easing cash collection frictions.

Guidance Reset and Heightened Uncertainty

ADMA withdrew longer‑term guidance and issued a more conservative 2026 outlook, calling for $530 million to $560 million in revenue and adjusted EBITDA of $265 million to $300 million. The updated view assumes continued ASCENIV growth but sustained pressure in standard IG and higher operating expenses for R&D and SG&A, while adjusted net income is projected between $170 million and $200 million.

ADMA’s earnings call painted a picture of a company leaning into its strengths, with ASCENIV, expanding margins and solid cash generation offsetting turbulence in the standard IG business. Investors will be watching how quickly the IG market normalizes and whether pipeline candidates like SG‑001 can unlock new growth, but for now the story centers on disciplined execution amid a challenging competitive landscape.